戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              FCAS was previously mapped to a 10-cM region on chromoso
2                    To identify the genes for FCAS and MWS, we screened exons in the 1q44 region for m
3 h equal potency in LPS-stimulated cells from FCAS and control subjects.
4 we examined cytokine secretion in PBMCs from FCAS patients and found a marked hyperresponsiveness of
5    Cryopyrin, the protein that is altered in FCAS, is one of the adaptor proteins that activate caspa
6 s occurring after a general cold exposure in FCAS patients and to investigate the effects of pretreat
7 s, that have hitherto been described only in FCAS and NOMID, respectively.
8 ory syndrome (FCAS), and 3 probands with MWS/FCAS.
9 ion in patients with NOMID/CINCA syndrome or FCAS.
10     Familial cold autoinflammatory syndrome (FCAS) and the related autoinflammatory disorders, Muckle
11     Familial cold autoinflammatory syndrome (FCAS) is an autosomal dominant disorder characterised by
12     Familial cold autoinflammatory syndrome (FCAS) is caused by mutations in the CIAS1 gene, leading
13 lial cold-induced autoinflammatory syndrome (FCAS), and 3 probands with MWS/FCAS.
14 S), familial cold autoinflammatory syndrome (FCAS), and neonatal-onset multisystem inflammatory disea
15 ing familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal onset m
16     Familial cold autoinflammatory syndrome (FCAS, MIM 120100), commonly known as familial cold urtic
17                               Patients whose FCAS was not completely controlled were allowed a dosage
18 ted with the disorder in three families with FCAS and one family with MWS.
19 fter cold challenge, untreated patients with FCAS developed rash, fever, and arthralgias within 1-4 h
20 cal and biochemical changes in patients with FCAS indicates a central role for interleukin 1beta in t
21                           Five patients with FCAS were studied in an open-label trial.
22 romising therapeutic option in patients with FCAS, and the data led to the design of a phase III stud
23 -1 receptor fusion protein, in patients with FCAS.
24 a on rilonacept treatment in 5 patients with FCAS.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。